Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. More Details
Solid track record with high growth potential.
Share Price & News
How has Neurocrine Biosciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NBIX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: NBIX's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: NBIX underperformed the US Biotechs industry which returned 31.3% over the past year.
Return vs Market: NBIX underperformed the US Market which returned 44.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Neurocrine Biosciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 days ago | Simply Wall StEarnings Not Telling The Story For Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
1 month ago | Simply Wall StWe Think Shareholders Are Less Likely To Approve A Large Pay Rise For Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) CEO For Now
1 month ago | Simply Wall StNeurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly
Is Neurocrine Biosciences undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NBIX ($98.61) is trading below our estimate of fair value ($295.22)
Significantly Below Fair Value: NBIX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NBIX is poor value based on its PE Ratio (22.9x) compared to the US Biotechs industry average (21.9x).
PE vs Market: NBIX is poor value based on its PE Ratio (22.9x) compared to the US market (19.7x).
Price to Earnings Growth Ratio
PEG Ratio: NBIX is good value based on its PEG Ratio (0.7x)
Price to Book Ratio
PB vs Industry: NBIX is overvalued based on its PB Ratio (7.7x) compared to the US Biotechs industry average (3.5x).
How is Neurocrine Biosciences forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NBIX's forecast earnings growth (32.4% per year) is above the savings rate (2%).
Earnings vs Market: NBIX's earnings (32.4% per year) are forecast to grow faster than the US market (15.5% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: NBIX's revenue (17.8% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: NBIX's revenue (17.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NBIX's Return on Equity is forecast to be high in 3 years time (27.9%)
How has Neurocrine Biosciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NBIX has a high level of non-cash earnings.
Growing Profit Margin: NBIX's current net profit margins (38.5%) are higher than last year (19.9%).
Past Earnings Growth Analysis
Earnings Trend: NBIX has become profitable over the past 5 years, growing earnings by 73.5% per year.
Accelerating Growth: NBIX's earnings growth over the past year (127.8%) exceeds its 5-year average (73.5% per year).
Earnings vs Industry: NBIX earnings growth over the past year (127.8%) exceeded the Biotechs industry -7.7%.
Return on Equity
High ROE: NBIX's Return on Equity (33.3%) is considered high.
How is Neurocrine Biosciences's financial position?
Financial Position Analysis
Short Term Liabilities: NBIX's short term assets ($1.1B) exceed its short term liabilities ($190.0M).
Long Term Liabilities: NBIX's short term assets ($1.1B) exceed its long term liabilities ($450.8M).
Debt to Equity History and Analysis
Debt Level: NBIX's debt to equity ratio (26.7%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if NBIX's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: NBIX's debt is well covered by operating cash flow (87%).
Interest Coverage: NBIX's interest payments on its debt are well covered by EBIT (13.8x coverage).
What is Neurocrine Biosciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NBIX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NBIX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NBIX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NBIX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NBIX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kevin Gorman (62 yo)
Dr. Kevin C. Gorman, Ph.D., has been the President and Chief Executive Officer of Neurocrine Biosciences, Inc. since January 2008. Dr. Gorman is a Founder of Neurocrine Biosciences, Inc. Dr. Gorman was Exe...
CEO Compensation Analysis
Compensation vs Market: Kevin's total compensation ($USD13.88M) is above average for companies of similar size in the US market ($USD6.52M).
Compensation vs Earnings: Kevin's compensation has increased by more than 20% in the past year.
Experienced Management: NBIX's management team is seasoned and experienced (6.4 years average tenure).
Experienced Board: NBIX's board of directors are seasoned and experienced ( 10.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Neurocrine Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Neurocrine Biosciences, Inc.
- Ticker: NBIX
- Exchange: NasdaqGS
- Founded: 1992
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$9.323b
- Shares outstanding: 94.55m
- Website: https://www.neurocrine.com
Number of Employees
- Neurocrine Biosciences, Inc.
- 12780 El Camino Real
- San Diego
- United States
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorder...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/13 23:28|
|End of Day Share Price||2021/06/11 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.